Assessment of Maternal and Fetal Serum Biomarkers in Women With Pre-eclampsia

SHAHLA KAREEM ALALAF204 enrolled

Overview

The findings of markers of placental dysfunction in women with preeclampsia may suggest that these biomarkers may be useful tools for early detection of preeclampsia

Preeclampsia is a pregnancy-specific hypertension illness that is characterized by widespread maternal endothelial dysfunction and appears to be a systemic syndrome that originates in the placenta. Through binding to and blocking the interaction of placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) with their receptors Flt1, soluble fms-like tyrosine kinase (sFlt1) functions as an antagonist of these growth factors. Most seromucoid and protein-bound hexose are released during an acute phase and are inflammatory glycoproteins. Hepatocytes in the liver, which are highly sensitive to stress, increase and leak into the bloodstream during any disease state. It is a time when the placenta demands more vascular development. In order to identify and explain the differences in sFLT-1, VEGF, PlGF levels, and inflammatory biomarker responses. Current study will investigate the differences in blood level of sFLT-1, VEGF, PLGF, Seromucoid and protein-bound hexose inflammatory biomarkers between those with PE (cases) and healthy pregnant women (controls).

Study Type

OBSERVATIONAL

Enrollment

204

Conditions

Inflammatory Markers Preeclampsia Severe Preeclampsia Mild Umbilical Cord Issue Inflammatory Response Serum Seromucoid in Pregnancy Protein-bound Hexose in Preeclampsia

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age group 18-45 years * Gestational age of 26-41 weeks at the time of diagnosis for preeclampsia * Delivered vaginally or abdominally * Being of any parity (para 1 and more) * Pregnancy being singleton or multiple pregnancies * Willingness to provide informed consent Exclusion Criteria: * Pregnant woman having chronic hypertension * Having Diabetes mellitus * The lady on medications that can affect inflammatory markers or blood pressure * Pregnant with fetal anomalies * Refused to involve in the research

Locations (1)

Hawler Medical University

Erbil, Kurdistan Region, Iraq

Outcomes

Primary Outcomes

To compare the levels of maternal and fetal serum soluble Fms-like tyrosine kinase-1 (sFlt-1), seromucoid, and protein-bound hexose between women with pre-eclampsia and a control group of healthy pregnant women.

To quantify and compare the concentrations of soluble Fms-like tyrosine kinase-1 (sFlt-1), seromucoid, and protein-bound hexose in maternal and fetal serum between women diagnosed with pre-eclampsia and a control group of normotensive pregnant women.

Time frame: one hour

Secondary Outcomes

To assess the association between the levels of these biomarkers and the severity of pre-eclampsia.

o quantify and compare the concentrations of soluble Fms-like tyrosine kinase-1 (sFlt-1), seromucoid, and protein-bound hexose in maternal and fetal serum between women diagnosed with pre-eclampsia and a control group of normotensive pregnant women.

Time frame: one hour

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.